Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage

Clinical Endocrinology
T LucasSpanish Multicentre Lanreotide Study Group on Acromegaly


The objective of this open study of 104 patients was to determine whether the somatostatin analogue lanreotide shrinks GH-secreting adenomas and to identify the predictive factors of a significant tumour volume reduction (> 20%). A total of 104 previously untreated and newly diagnosed acromegalic patients received the prolonged release (PR) formulation of lanreotide (lanreotide 30 mg, one intramuscular injection every 10 days) for either 1 (n = 84), 2 (n = 13), or 3 or more (n = 7) months before transsphenoidal surgery. Pituitary tumour volumes, tumour extension grade and possible cavernous sinus invasion were assessed in blinded conditions by a centralized team of radiologists. Factors such as demographics, tumour characteristics, GH and IGF-I levels were evaluated as possible predictive factors of a significant tumour volume reduction. The clinical activity and random GH, IGF-I, IGFBP-3, PRL, TSH, free T4 and lanreotide levels serum concentrations were measured under basal conditions and in the 10 days before surgery. All analyses were done in a centralized laboratory. The tolerability of preoperative PR lanreotide and the surgical outcome at the 6th month after surgery were assessed. The presurgical treatment improved the sy...Continue Reading


Nov 1, 1992·Annals of Internal Medicine·S EzzatD M Cook
Jul 1, 1992·Journal of Computer Assisted Tomography·P Lundin, F Pedersen
Dec 19, 1985·The New England Journal of Medicine·S W LambertsE del Pozo
Jul 1, 1986·Journal of Neurosurgery·G TolisS Pitoulis
Mar 1, 1987·The Journal of Clinical Endocrinology and Metabolism·P G ChiodiniE del Pozo
Apr 1, 1971·Journal of Neurosurgery·J Hardy
Jan 1, 1980·Clinical Endocrinology·L AlexanderR Wilkinson
Apr 1, 1995·Neurosurgery·M J PuchnerD K Lüdecke
Nov 1, 1994·The American Journal of Medicine·Acromegaly Therapy Consensus Development Panel
Dec 1, 1994·The American Journal of the Medical Sciences·A Y Krishna, L S Phillips
Feb 1, 1993·Irish Journal of Medical Science·J A O'HareT Cotter
Mar 1, 1993·Journal of Endocrinological Investigation·J EtxabeJ A Vazquez
Jan 25, 1996·The New England Journal of Medicine·S W LambertsL J Hofland
Feb 1, 1996·The Journal of Clinical Endocrinology and Metabolism·L A Frohman
Oct 1, 1996·Clinical Endocrinology·M al-MaskariP Kendall-Taylor
Nov 5, 1997·The Journal of Clinical Endocrinology and Metabolism·A ColaoG Lombardi
Oct 13, 1998·The Journal of Clinical Endocrinology and Metabolism·A AboschC B Wilson
Jun 1, 1962·The Journal of Clinical Endocrinology and Metabolism·G M MOLINATTIG GIULIANI
Dec 1, 1948·Journal of the American Statistical Association·A H BOWKER


Aug 21, 2012·Pituitary·Shlomo MelmedA Giustina
Feb 16, 2005·Reviews in Endocrine & Metabolic Disorders·David Kleinberg
Dec 29, 2007·Reviews in Endocrine & Metabolic Disorders·Zachary M Bush, Mary Lee Vance
Jun 18, 2009·Advances in Therapy·F CastinettiT Brue
Nov 14, 2012·Therapeutic Advances in Endocrinology and Metabolism·Zelija Velija-Asimi
Aug 27, 2009·Biologics : Targets & Therapy·Ferdinand RoelfsemaJohannes A Romijn
Jun 10, 2008·Expert Opinion on Emerging Drugs·Philippe Chanson
Apr 7, 2009·Annales d'endocrinologie·F CastinettiT Brue
Jan 30, 2008·Endocrinology and Metabolism Clinics of North America·Anat Ben-Shlomo, Shlomo Melmed
Jan 15, 2008·Molecular and Cellular Endocrinology·Anat Ben-Shlomo, Shlomo Melmed
Aug 22, 2006·Clinical Endocrinology·T LucasSpanish-Portuguese Multicentre Autogel Study Group on Acromegaly
Jul 16, 2013·Clinical Endocrinology·Nadège C van VarsseveldMadeleine L Drent
Apr 24, 2012·Annales d'endocrinologie·Philippe Chanson, Peter Kamenický
Sep 20, 2005·The Journal of Medical Investigation : JMI·Weiping LiuSeigo Nagao
May 27, 2014·Pituitary·E Fernandez-RodriguezI Bernabeu
Mar 31, 2011·Nature Reviews. Endocrinology·Mark SherlockMichael C Sheppard
Aug 26, 2006·Nature Clinical Practice. Endocrinology & Metabolism·Laurence Katznelson
Oct 27, 2009·Drugs·Richard A FeeldersA J van der Lely
Dec 3, 2010·Endocrine Reviews·A ColaoRosario Pivonello
Mar 1, 2007·Expert Review of Endocrinology & Metabolism·R Cozzi, Roberto Attanasio
Mar 1, 2012·Expert Review of Endocrinology & Metabolism·Josefine Roemmler, Jochen Schopohl
Mar 7, 2012·Expert Review of Clinical Pharmacology·R Cozzi, Roberto Attanasio
Apr 14, 2005·The Journal of Clinical Endocrinology and Metabolism·Shlomo MelmedA L Barkan
Jul 1, 2007·Expert Review of Endocrinology & Metabolism·Marianne Andersen

Related Concepts

Lanreotide acetate
Adenoma, Trabecular
Antineoplastic Agents
Combined Modality Therapy
Insulin-Like Growth Factor I
Cyclic Peptides
Pituitary Carcinoma
Recombinant Growth Hormone
Tumor Markers

Related Feeds

Absence Epilepsy

Absence epilepsy is a common seizure disorder in children which can produce chronic psychosocial sequelae. Discover the latest research on absence epilepsies here.